Kohjin BioKohjin Bio Co., Ltd.177A東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP

Kohjin Bio revenue and profit

Name: Kohjin Bio financial data
Creator: Vizora

Out of every ¥100 of sales, about ¥7 is left as operating profit. Revenue changed -5.1% from the prior year, operating profit -65.5%.

Five-year trend

Revenue¥4.94B

Operating income¥341.5M

Operating margin6.9%

What drives ROE

Net margin × asset turnover = ROA; ROA × financial leverage = ROE

Net margin5.1%

Asset turnover0.55×

ROA2.8%

Financial leverage1.57×

ROE4.4%

Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.

Net margin5.1%

Asset turnover0.55×

ROA2.8%

Financial leverage1.57×

ROE4.4%

Period	Net margin	Asset turnover	ROA	Financial leverage	ROE
2023	17.5%	0.77×	13.5%	2.06×	27.9%
2024	8.1%	0.75×	6.1%	2.03×	12.3%
2025	15.3%	0.67×	10.2%	1.75×	17.8%
2026	5.1%	0.55×	2.8%	1.57×	4.4%

Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.

Asset intensity and goodwill

Annual trends in tangible-asset ratios and goodwill balance.

PPE ÷ revenue76.9%

PPE ÷ total assets42.7%

Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition

Investment and working-capital efficiency

Track R&D investment and how long operating capital remains tied up before sales turn into cash.

R&D spending¥250M

R&D / revenue5.1%

Payable days14d

R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.

Income statement (JPY millions)

Item	FY ending Mar 2023	FY ending Mar 2024	FY ending Mar 2025	FY ending Mar 2026
Revenue	4,743	4,770	5,206	4,939
Cost of revenue	2,289	2,889	2,840	3,082
Gross profit	2,454	1,881	2,366	1,857
SG&A	1,187	1,284	1,375	1,516
Operating income	1,267	597	991	342
Pretax income	1,244	636	1,015	332
Income tax	415	251	221	81
Net income attributable to owners	830	385	795	251
Operating margin	26.7%	12.5%	19.0%	6.9%

Balance sheet (reported items)

Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.

Assets

Cash 28%

Property, plant and equipment 43%

Other assets 22%

Funding

Other liabilities 32%

Equity 67%

Each bar totals 100% of assets; other is the residual.

Item	FY ending Mar 2023	FY ending Mar 2024	FY ending Mar 2025	FY ending Mar 2026
Cash and equivalents	¥1.46B	¥1.73B	¥2.95B	¥2.49B
Total assets	¥6.13B	¥6.59B	¥9.07B	¥8.9B
Net assets	¥3.02B	¥3.34B	¥5.78B	¥5.95B
Share capital	¥426.7M	¥426.7M	¥1.25B	¥1.25B
Property, plant and equipment	¥2.17B	¥2.59B	¥3.25B	¥3.8B
Intangible assets excluding goodwill	¥4.4M	¥3M	¥27.3M	¥18.9M
Investment securities	¥409.6M	¥481.9M	¥581.3M	¥661M
Current assets	¥3.48B	¥3.41B	¥5.07B	¥4.27B
Current liabilities	¥3.02B	¥2.4B	¥2.49B	¥2.37B
Trade payables	¥146.3M	¥163.5M	¥134.1M	¥117M
Short-term borrowings	¥1.2B	¥1.5B	¥1.5B	¥1.5B
Long-term borrowings	—	¥525M	¥375M	¥225M
Total liabilities	¥3.12B	¥3.25B	¥3.28B	¥2.96B
Equity attributable to owners of parent	¥2.98B	¥3.28B	¥5.67B	¥5.8B
Retained earnings	¥2.22B	¥2.53B	¥3.27B	¥3.39B

Sources

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第45期(2025/04/01－2026/03/31)
ID S100YB5D2026-06-23Open
EDINET (FSA Japan)
有価証券報告書－第44期(2024/04/01－2025/03/31)
ID S100W2HI2025-06-24Open
EDINET (FSA Japan)
有価証券報告書－第43期(2023/04/01－2024/03/31)
ID S100TX402024-06-28Open

Extracted from XBRL: 48 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open Markdown Share on X Save image